Europe

View All
September 29, 2022 0

4D pharma will not report it’s half year interim results

By Dino Mustafić

4D pharma will not report its interim results for the 6 months to 30 June 2022 by 30 September as required by Rule 18 of the AIM Rules for Companies,...

USA

View All
April 29, 2022 Off

FDA Approves BMS’s Camzyos for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM)

By Author

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment...

My Pharmaceutical

View All
April 13, 2022 Off

Allergan’s BOTOX Cosmetic Celebrates 20th Birthday

By Author

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is celebrating 20th anniversary of FDA's approval of Botox Cosmetic.

April 13, 2022 Off

EMA and the EUnetHTA 21 consortium set priorities for their collaboration

By Author

The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) 21 consortium have published a  joint work plan until 2023....

April 4, 2022 Off

Sanofi Launches First-In-Pharma Diversity, Equity & Inclusion Board

By Author

Sanofi has launched its Diversity, Equity & Inclusion (DE&I) Board, the first-of-its-kind in the pharmaceutical industry to feature outside advisors....